ArticleMedicine2025
Triptolide combined with arsenic trioxide induces apoptosis of myelodysplastic syndrome cells by inhibiting the NF-κB signaling pathway.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe aim of this study was to delve into the combined effects of triptolide (TL) and arsenic trioxide (ATO) on the proliferation and apoptosis of myelodysplastic syndrome (MDS) cells, in addition to exploring the important role of the NF-κB signaling pathway underlying these combined actions.
methodsThe MDS cells SKM-1 were treated with TL, ATO, and TL combined with ATO, respectively. The CCK-8 kit was used to detect proliferation viability in each group. Flow cytometry with Annexin V-FITC/PI double staining was employed to investigate the rate of apoptosis. The expression levels of mRNA and proteins related to apoptotic molecules, along with key molecules of the NF-κB signaling pathway, were meticulously detected in each group by real-time quantitative polymerase chain reaction and western blot.
resultsTL in combination with ATO exhibited a pronounced inhibitory effect on the proliferation of SKM-1 cells (P<.0001), and the combined actions also triggered apoptosis in SKM-1 cells. The proliferation inhibition rate and apoptosis rate of the combined treatment group were significantly elevated compared to those of the individual drug groups (P<.05). Upon the integration of TL and ATO, the concentration of PARP cleavage protein escalates, and the mRNA and protein expressions of the executioner caspase, including Caspase3 and Caspase8, experience a marked elevation. Conversely, the mRNA and protein expressions of the anti-apoptotic genes Bcl-2, Bcl-XL, and cIAP1 undergo a significant reduction.
conclusionThe combined impact of TL and ATO amplifies the expression of p65 within the canonical NF-κB signaling pathway, while inhibiting the expression of IkBα, p52, and RelB in the noncanonical pathway. The combination effect of TL and ATO markedly suppresses the proliferation of MDS cells and induces apoptosis collaboratively, which potentially occurs through a mechanism by inhibiting the NF-κB signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.